论文部分内容阅读
目的 回顾21例多发性骨髓瘤(MM)患者皮下注射万珂(共278针)后发生注射部位反应(ISR)的风险和严重程度.方法 21例多发性骨髓瘤(MM)患者中11例MM患者万珂药物浓度为1mg/ml,10例MM患者万珂药物浓度为2.5mg/ml.患者和医护人员都了解化疗方案,由有资质的护士按照标准皮下注射手法,根据 8 点轮换注射法要求进行皮下注射给药.单次皮下注射剂量>2ml者,分2针同时在8点中临近的2个部位注射.首轮首次注射后2小时开始评估,并在下轮注射前每日进行评估.第2轮及以后,每次注射后评估,患者在院外期间每日自行评估并记录.结果 万珂皮下注射浓度为2.5mg/ml时,大腿发生2级ISR的风险高于腹部,有统计学差异(P<0.05);浓度为1.0mg/ml时患者发生2级ISR的风险低于浓度为2.5mg/ml时,有统计学差异(P 2 ml, 2 needles were injected at two adjacent parts of the injection in 8 points at the same time. The tolerability of scBor at the injection site was evaluated systematically 2–hrs after injection and every day during the first treatment cycle during hospitalization. After the second cycle, ISRs were evaluated at every visit, and between visits, patients documented their own ISRs in a detailed diary.Result: A higher incidence of grade 2 ISR in the thigh compared with the abdomen (concentration of 2.5 mg/ml,P <0.05) can be indicated;the incidence of grade 2 ISR is higher in patients whom were treated with scBor at a concentration of 2.5 mg/ml than in those whom were treated with scBor at a concentration of 1.0 mg/ml.Conclusion:The subcutaneous injection method of bortezomib including low concentration (1.0 mg/ml) and limit volume(<2ml) may reduce the risk of injection site reactions, improve the safety of the treatment.